Fig. 4: Parity-induced protection against breast cancer is mediated by CD8+ T cells.
From: Parity and lactation induce T-cell-mediated breast cancer protection
a, AT3-OVA tumour growth (left) and end-point tumour burden (right) in the fourth MFP of Rag2−/−Il2rg−/− d28-inv (n = 13) and age-matched virgin control (n = 14) mice. b, AT3-OVA tumour growth (left) and end-point tumour burden (right) in the fourth MFP of Rag2−/−Il2rg−/− d28-inv (n = 11) and age-matched virgin control (n = 10) mice pre-inoculated with OT-I cells 7 days before mating. c, The numbers of the indicated immune cells per gram of AT3-OVA tumour from virgin (n = 6) and d28-inv (n = 6) Rag2−/−Il2rg−/− mice at 4 weeks after tumour development. d, AT3-OVA tumour growth in the fourth MFP of virgin (left) and d28-inv (right) C57BL/6 mice treated with anti-CD4 (virgin, n = 12; d28-inv, n = 13), anti-CD8α (n = 9), anti-CD8β (virgin, n = 12; d28-inv, n = 14) and combined anti-CD4/CD8α (n = 14) or isotype control (n = 16). e, End-point AT3-OVA tumour weight in virgin (left) and d28-inv (right) C57BL/6 mice depleted with anti-CD4 (virgin, n = 12; d28-inv, n = 13), anti-CD8α (n = 9), anti-CD8β (virgin, n = 12; d28-inv, n = 14) and combined anti-CD4/CD8α (n = 14) or isotype control (n = 16). f, The numbers of CD3+ T cells per μl blood in virgin and d28-inv C57BL/6 mice treated with FTY720 (n = 8) or vehicle (n = 8). g, AT3-OVA tumour growth after treatment with FTY720 at the indicated timepoints (virgin, n = 11; d28-inv, n = 15) or treatment with vehicle (virgin, n = 12; d28-inv, n = 15). h, End-point AT3-OVA tumour weight in virgin and d28-inv C57BL/6 mice treated with FTY720 (virgin, n = 11; d28-inv, n = 15) or vehicle (virgin, n = 12; d28-inv, n = 15). i, The number of OVA-tetramer+ T cells per gram of AT3-OVA tumour (virgin, n = 10; d28-inv, n = 13) or vehicle (virgin, n = 10; d28-inv, n = 15) analysed 23–25 days after breast cancer tumour cell injection. Data are mean ± s.e.m. from two combined independent experiments. Statistical analysis was performed using two-sided Mann–Whitney U-tests (a–c), two-way analysis of variance (ANOVA) at the end point (d and g), Kruskal–Wallis tests (f and i) and one-way ANOVA (e and h). Exact P values are shown, or P < 0.0001 in cases in which P values are very small.
